We are analyzing https://link.springer.com/article/10.1007/s10555-022-10066-y.

Title:
The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options | Cancer and Metastasis Reviews
Description:
Hormonal therapy plays a vital part in the treatment of estrogen receptor–positive (ER +) breast cancer. ER can be activated in a ligand-dependent and independent manner. Currently available ER-targeting agents include selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), and aromatase inhibitors (AIs). Estrogen receptor mutation (ESR1 mutation) is one of the common mechanisms by which breast cancer becomes resistant to additional therapies from SERMs or AIs. These tumors remain sensitive to SERDs such as fulvestrant. Fulvestrant is limited in clinical utilization by its intramuscular formulation and once-monthly injection in large volumes. Oral SERDs are being rapidly developed to replace fulvestrant with the potential of higher efficacy and lower toxicities. Elacestrant is the first oral SERD that went through a randomized phase III trial showing increased efficacy, especially in tumors bearing ESR1 mutation, and good tolerability. Two other oral SERDs recently failed to achieve the primary endpoints of longer progression-free survival (PFS). They targeted tumors previously treated with several lines of prior therapies untested for ESR1 mutation. Initial clinical trial data demonstrated that tumors without the ESR1 mutation are less likely to benefit from the SERDs and may still respond to SERMs or AIs, including tumors previously exposed to hormonal therapy. Testing for ESR1 mutation in ongoing clinical trials and in hormonal therapy for breast cancer is highly recommended. Novel protein degradation technologies such as proteolysis-targeting chimera (PROTACS), molecular glue degrader (MGD), and lysosome-targeting chimeras (LYTACS) may result in more efficient ER degradation, while ribonuclease-targeting chimeras (RIBOTAC) and small interfering RNA (siRNA) may inhibit the production of ER protein.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

cancer, breast, article, estrogen, google, scholar, receptor, oral, clinical, therapy, fulvestrant, patients, serds, cas, phase, protein, trial, esr, degradation, study, treatment, advanced, mutation, endocrine, journal, research, target, selective, trials, inhibitors, ais, serd, metastatic, oncology, efficacy, elacestrant, palbociclib, degrader, tamoxifen, cdk, versus, protac, tumors, iii, amcenestrant, giredestrant, pfs, proteins, receptorpositive, randomized,

Topics {✒️}

er + /her2 − unresectable loco-regional recurrent er + /her2 − unresectable loco-regional advanced recruits 2ʹ-5ʹ-linked tetra-adenylate hormone-receptor-positive locally advanced er + /her2-negative locally advanced estrogen-receptor positive endocrine-resistant er + /her2 − early breast cancer shou-ching tang exhibits anti-tumor activity er/pr-positive mbc involve early-stage breast cancer erbb2-negative breast cancer her2 − advanced breast cancer gov/archive/csr/1975_2011/ esr-bearing breast cancers er + /her2 − locally advanced er+/her2- locally advanced article download pdf human bag-1/rap46 protein nucleic acid–based tool er + metastatic breast cancer metastatic er + breast cancer hr + metastatic breast cancer nuclear-initiated steroid signaling endocrine-resistant breast cancer growth factor receptors nucleic acid–based agents membrane-initiated steroid signaling lysosome-targeting chimeras evolve enhances protein–protein interactions prevent er + breast cancers ligand-dependent transcription factors selective estrogen modulators open-label multicenter study preferentially inhibits proliferation suppress er + breast cancer catalytic subunit α molecular therapy-nucleic acids targeting egfr/her2/her3 selective estrogen receptor inhibiting er + breast cancer estrogen receptor isoforms/variants anti-her2 therapy tumors expressing wild-type treatment-related adverse events hormone receptor–positive hormone receptor-positive hormone-receptor positive effectively target membrane-bound regulate cell growth

Questions {❓}

Are estrogen receptors cytoplasmic or nuclear?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options
         description:Hormonal therapy plays a vital part in the treatment of estrogen receptor–positive (ER +) breast cancer. ER can be activated in a ligand-dependent and independent manner. Currently available ER-targeting agents include selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), and aromatase inhibitors (AIs). Estrogen receptor mutation (ESR1 mutation) is one of the common mechanisms by which breast cancer becomes resistant to additional therapies from SERMs or AIs. These tumors remain sensitive to SERDs such as fulvestrant. Fulvestrant is limited in clinical utilization by its intramuscular formulation and once-monthly injection in large volumes. Oral SERDs are being rapidly developed to replace fulvestrant with the potential of higher efficacy and lower toxicities. Elacestrant is the first oral SERD that went through a randomized phase III trial showing increased efficacy, especially in tumors bearing ESR1 mutation, and good tolerability. Two other oral SERDs recently failed to achieve the primary endpoints of longer progression-free survival (PFS). They targeted tumors previously treated with several lines of prior therapies untested for ESR1 mutation. Initial clinical trial data demonstrated that tumors without the ESR1 mutation are less likely to benefit from the SERDs and may still respond to SERMs or AIs, including tumors previously exposed to hormonal therapy. Testing for ESR1 mutation in ongoing clinical trials and in hormonal therapy for breast cancer is highly recommended. Novel protein degradation technologies such as proteolysis-targeting chimera (PROTACS), molecular glue degrader (MGD), and lysosome-targeting chimeras (LYTACS) may result in more efficient ER degradation, while ribonuclease-targeting chimeras (RIBOTAC) and small interfering RNA (siRNA) may inhibit the production of ER protein.
         datePublished:2022-10-14T00:00:00Z
         dateModified:2022-10-14T00:00:00Z
         pageStart:975
         pageEnd:990
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s10555-022-10066-y
         keywords:
            Selective estrogen receptor degraders
            Clinical trials
            Protein degradation
            Oral SERDs
            PROTC
            LYTAC
            RIBOTAC
            Aptamers
            Cancer Research
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-022-10066-y/MediaObjects/10555_2022_10066_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-022-10066-y/MediaObjects/10555_2022_10066_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-022-10066-y/MediaObjects/10555_2022_10066_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-022-10066-y/MediaObjects/10555_2022_10066_Fig4_HTML.png
         isPartOf:
            name:Cancer and Metastasis Reviews
            issn:
               1573-7233
               0167-7659
            volumeNumber:41
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yating Wang
               affiliation:
                     name:Ascension Providence Hospital
                     address:
                        name:Ascension Providence Hospital, Southfield, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shou-Ching Tang
               url:http://orcid.org/0000-0001-5535-4453
               affiliation:
                     name:University of Mississippi Medical Center, Guyton Research Building
                     address:
                        name:Cancer Center and Research Institute, University of Mississippi Medical Center, Guyton Research Building, Jackson, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options
      description:Hormonal therapy plays a vital part in the treatment of estrogen receptor–positive (ER +) breast cancer. ER can be activated in a ligand-dependent and independent manner. Currently available ER-targeting agents include selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), and aromatase inhibitors (AIs). Estrogen receptor mutation (ESR1 mutation) is one of the common mechanisms by which breast cancer becomes resistant to additional therapies from SERMs or AIs. These tumors remain sensitive to SERDs such as fulvestrant. Fulvestrant is limited in clinical utilization by its intramuscular formulation and once-monthly injection in large volumes. Oral SERDs are being rapidly developed to replace fulvestrant with the potential of higher efficacy and lower toxicities. Elacestrant is the first oral SERD that went through a randomized phase III trial showing increased efficacy, especially in tumors bearing ESR1 mutation, and good tolerability. Two other oral SERDs recently failed to achieve the primary endpoints of longer progression-free survival (PFS). They targeted tumors previously treated with several lines of prior therapies untested for ESR1 mutation. Initial clinical trial data demonstrated that tumors without the ESR1 mutation are less likely to benefit from the SERDs and may still respond to SERMs or AIs, including tumors previously exposed to hormonal therapy. Testing for ESR1 mutation in ongoing clinical trials and in hormonal therapy for breast cancer is highly recommended. Novel protein degradation technologies such as proteolysis-targeting chimera (PROTACS), molecular glue degrader (MGD), and lysosome-targeting chimeras (LYTACS) may result in more efficient ER degradation, while ribonuclease-targeting chimeras (RIBOTAC) and small interfering RNA (siRNA) may inhibit the production of ER protein.
      datePublished:2022-10-14T00:00:00Z
      dateModified:2022-10-14T00:00:00Z
      pageStart:975
      pageEnd:990
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s10555-022-10066-y
      keywords:
         Selective estrogen receptor degraders
         Clinical trials
         Protein degradation
         Oral SERDs
         PROTC
         LYTAC
         RIBOTAC
         Aptamers
         Cancer Research
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-022-10066-y/MediaObjects/10555_2022_10066_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-022-10066-y/MediaObjects/10555_2022_10066_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-022-10066-y/MediaObjects/10555_2022_10066_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-022-10066-y/MediaObjects/10555_2022_10066_Fig4_HTML.png
      isPartOf:
         name:Cancer and Metastasis Reviews
         issn:
            1573-7233
            0167-7659
         volumeNumber:41
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yating Wang
            affiliation:
                  name:Ascension Providence Hospital
                  address:
                     name:Ascension Providence Hospital, Southfield, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shou-Ching Tang
            url:http://orcid.org/0000-0001-5535-4453
            affiliation:
                  name:University of Mississippi Medical Center, Guyton Research Building
                  address:
                     name:Cancer Center and Research Institute, University of Mississippi Medical Center, Guyton Research Building, Jackson, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer and Metastasis Reviews
      issn:
         1573-7233
         0167-7659
      volumeNumber:41
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Ascension Providence Hospital
      address:
         name:Ascension Providence Hospital, Southfield, USA
         type:PostalAddress
      name:University of Mississippi Medical Center, Guyton Research Building
      address:
         name:Cancer Center and Research Institute, University of Mississippi Medical Center, Guyton Research Building, Jackson, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yating Wang
      affiliation:
            name:Ascension Providence Hospital
            address:
               name:Ascension Providence Hospital, Southfield, USA
               type:PostalAddress
            type:Organization
      name:Shou-Ching Tang
      url:http://orcid.org/0000-0001-5535-4453
      affiliation:
            name:University of Mississippi Medical Center, Guyton Research Building
            address:
               name:Cancer Center and Research Institute, University of Mississippi Medical Center, Guyton Research Building, Jackson, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Ascension Providence Hospital, Southfield, USA
      name:Cancer Center and Research Institute, University of Mississippi Medical Center, Guyton Research Building, Jackson, USA

External Links {🔗}(210)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Ember.js
Knockout.js
Prism.js

CDN Services {📦}

Crossref

4.96s.

LINK . SPRINGER . COM {}